Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Hofteudskiftningssystem (HRS-P) ved primær total hoftearthroplastik ((HRS-P))

16. september 2026 opdateret af: Hip Innovation Technology

En multi-center prospektiv undersøgelse af hofteinnovationsteknologien (HIT) hofteudskiftningssystemet i primær total hoftearthroplastik

To evaluate effectiveness and safety of HHRS in subjects undergoing total hip arthroplasty (THA). Effectiveness will be evaluated using patient-reported, clinical, radiologic, and radiostereometric outcomes. Safety will be evaluated through the collection of device-related and unanticipated device-related adverse events.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The HIT Hip Replacement System (HHRS) is a Metal-on-Polyethylene (MoP) conventional hip prosthesis. The HHRS consists of a femoral stem, an acetabular cup and a Cobalt Chromium Molybdenum (CoCrMo) ball that articulates within a polyethylene liner. The ball sits on the acetabular cup, and the polyethylene liner is attached to the femoral cup, which attaches to the femoral stem, instead of the acetabular cup. The acetabular component of the HHRS consists of a hemispherical acetabular shell with a clustered screw-hole design. The outside of the shells are coated with titanium plasma to facilitate bone in-growth and provide secure intermediate fixation with the prepared bone surface at the site of implantation. The acetabular cup has a 3-hole design that accommodates three titanium alloy bone screws. Inside the acetabular cup is a male taper for assembly with the acetabular ball. The femoral component consists of a femoral stem manufactured from titanium and a mating cobalt chrome femoral cup lined with a highly cross-linked ultra-high-molecular-weight polyethylene (UHMWPE). As with the acetabular cup, the femoral stem is porous coated using a plasma spray of pure titanium, which is intended to facilitate bone in-growth and provide secure intermediate fixation with the prepared bone surface at the site of implantation. The femoral stem incorporates a female taper for assembly with the male taper of the femoral cup.

The device has undergone extensive pre-clinical testing. There is no clinical experience with the HRS.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Manitoba
      • Winnipeg, Manitoba, Canada, R2K 2M9
        • Rekruttering
        • Orthopaedic Innovation Centre
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Thomas Turgeon, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

65 år til 79 år (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patient has a non-inflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses such as osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fracture of the pelvis, and diastrophic variant requiring unilateral primary total hip replacement.
  • Age between 65 and 79 years (inclusive) at the time of enrollment.
  • Patient is a suitable candidate for primary total hip replacement at the discretion of the Investigator.
  • Pre-surgery (within 28 days before surgery) WOMAC Global Score of 40 or larger on a scale from 0 (best) to 96 (worst)
  • Signed and dated informed consent document.
  • Patient is willing and able to participate in required follow-up visits at the Investigational site and to complete study procedures and questionnaires.

Exclusion Criteria:

  • Patient has had total hip replacement, hemi-arthroplasty, or fusion in either hip in the last 12 months;
  • Patient has planned total hip arthroplasty on a contra-lateral joint in the next 12 months;
  • Patient has a known allergy to any component of the study device;
  • Patient has a history of active sepsis in the joint;
  • Patient has an insufficient acetabular or femoral bone stock in which good anchorage of the implants are unlikely or impossible;
  • Patient has total or partial absence of the muscular or ligamentous apparatus;
  • Patient has known moderate to severe renal insufficiency;
  • Patient has vascular insufficiency, muscular atrophy, or neuromuscular disease in either leg (based on the Investigator's discretion);
  • Patient has a deformity of the affected limb or significant anatomic variance of the affected hip;
  • Patient has an active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix definitively treated more than 1 year prior to enrollment may enter the study;
  • Patient has any condition which may, in the opinion of the Investigator, interfere with the total hip replacement survival or patient outcomes (e.g. Paget's disease, Charcot's disease);
  • Patient has rheumatoid arthritis or other autoimmune condition that affect joints (e.g. Lupus Arthritis);
  • Patient has any condition that would interfere with patient self-assessment or pain, the function or quality of life required for patient reported outcomes during the study (based on the Investigator's discretion);
  • Body Mass Index (BMI) of 40 or more;
  • Patient has an active infection (e.g. hepatitis, AIDS, ARC) - systemic or at the site of intended surgery;
  • Patient is currently participating in any investigational study not related to this study's pre-operative or post-operative care;
  • Patient has any other severe acute or chronic medical condition that may interfere with the interpretation of the study results, in the judgment of the Investigator, which would make the patient inappropriate for entry into this study;
  • Patient has a history of metabolic bone disease (e.g. Paget's disease or osteomalacia);
  • Patient is currently pregnant or is planning to become pregnant.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: HIT Hip Replacement System (HRS)

Single group assignment with historical controls.

HIT Hip Replacement System

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Ændring i Western Ontario og McMaster Universities Osteoarthritis Index (WOMAC) v3.0 Likert Scale Functional Limitations Score mellem baseline (præ-operativt) og 730-dages post-operative opfølgningstidspunkt.
Tidsramme: mellem præoperativ og 730 dage (24 måneder)
mellem præoperativ og 730 dage (24 måneder)
Ændring i Harris Hip Score mellem baseline (præ-operativ) og 730-dages post-operative opfølgningstidspunkt.
Tidsramme: mellem præoperativ og 730 dage (24 måneder)
mellem præoperativ og 730 dage (24 måneder)

Sekundære resultatmål

Resultatmål
Tidsramme
Ændring i Oxford Hip Score mellem 730 dage efter operation og baseline (før operation)
Tidsramme: mellem 730 dage efter operation og baseline (før operation)
mellem 730 dage efter operation og baseline (før operation)
Ændring i Short Form 36 v2 Physical Component Score (PCS) mellem 730 dage efter operationen og baseline (før operationen)
Tidsramme: mellem 730 dage efter operation og baseline (før operation)
mellem 730 dage efter operation og baseline (før operation)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Thomas Turgeon, MD, Orthopaedic Innovation Centre
  • Studieleder: Branko Kopjar, MD, PhD, Nor Consult, LLC

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

25. august 2017

Primær færdiggørelse (Anslået)

16. september 2029

Studieafslutning (Anslået)

16. september 2032

Datoer for studieregistrering

Først indsendt

14. juli 2016

Først indsendt, der opfyldte QC-kriterier

15. juli 2016

Først opslået (Anslået)

18. juli 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • HIT-001

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner